General Gynecology Breast Health

Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women

Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR

Published August 2010 Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 19(8), 2073-2079
DOI 10.1158/1055-9965.EPI-10-0428 PMID 20647407 PMC PMC2919607

RRM Academy Synopsis

Oral contraceptives linked to ER-negative breast cancer in Black women

A follow-up study of 53,848 African-American women found that oral contraceptive use was more strongly associated with ER−PR− than ER+PR+ breast cancer. The rate ratio for ever use was 1.65 for ER−PR− tumors and 1.11 for ER+PR+ tumors, against women who had not used them.

Key Findings

  • The IRR for ever use was 1.65 (95% CI 1.19–2.30) among 279 ER−PR− cases and 1.11 (95% CI 0.86–1.42) among 386 ER+PR+ cases.
  • Among recent users (use extending into the previous five years), the ER−PR− IRR rose with duration, reaching 2.52 (95% CI 1.43–4.45) at 10 or more years (p trend = 0.001).
  • A case-only comparison of ER−PR− with ER+PR+ cancer gave an IRR of 1.57 (95% CI 1.27–1.92) for ever use, a significant difference between the two receptor types.
  • ER+PR+ results were null for most categories of duration and time since last use. Recent users with 10 or more years of use had an IRR of 1.66 (95% CI 1.01–2.74).
  • Among all 1,392 breast cancer cases regardless of receptor status, the IRR for ever use was 1.09 (95% CI 0.96–1.24).

Interpretation

This cohort study tracked 53,848 women enrolled in the Black Women's Health Study over a twelve-year span starting in 1995. Every two years the women answered a health survey that logged their contraceptive history. Researchers controlled for age, body mass index at 18, number of pregnancies and other known breast cancer risk factors. ER−PR− risk also ran higher among women with shorter or less recent pill use. The authors conclude that newer pill formulas carry added breast cancer risk for African-American women, with the sharper rise seen in ER− disease. They call for more research into what drives this ER− pattern.

RRM Context

Oral contraceptives are suppressive medications. They override the ovulatory cycle. Restorative reproductive medicine begins with a question: why is this cycle irregular or painful? The paper's introduction cites an earlier combined analysis of many studies. It estimated that current users carried a 25% higher breast cancer risk, largely gone by 10 years after use ended. The Black Women's Health Study adds data on tumor receptor type for African-American women.

Abstract

Background

Oral contraceptive formulations have changed over time, making it relevant to assess the effect of more recent formulations on breast cancer risk. In addition, some studies have found stronger positive associations of oral contraceptive use with estrogen receptor-negative (ER(-)) than with ER-positive (ER(+)) breast cancer. We carried out the first assessment of the effect of oral contraceptive use on the incidence of breast cancer classified by receptor status among African American women, a group disproportionately affected by ER(-) cancer.

Methods

We followed 53,848 Black Women's Health Study participants from 1995 to 2007 through biennial health questionnaires, in which participants reported information about incident breast cancer, oral contraceptive use, and breast cancer risk factors. Pathology information was obtained on receptor status for 789 incident cases. Incidence rate ratios (IRR) with 95% confidence intervals (95% CI) were derived from Cox regression models with control for confounding factors.

Results

Ever use of oral contraceptives was more strongly associated with ER(-)PR(-) breast cancer (279 cases; IRR, 1.65; 95% CI, 1.19-2.30) than with ER(+)PR(+) cancer (386 cases; IRR, 1.11; 95% CI, 0.86-1.42). The risk of ER(-)PR(-) breast cancer increased with increasing duration of use among recent users.

Conclusions

These results indicate that the oral contraceptive formulations used in recent decades increase breast cancer risk in African American women, with a greater effect for ER(-) than ER(+) cancer.

Impact

Mechanisms to explain the adverse influence of oral contraceptive use on ER(-) breast cancer need to be elucidated.

Topics

By this author

Related research

General Gynecology › Breast Health › Breast Cancer Risk · Contraception › Oral Contraceptives › Cancer Risk
Lynn Rosenberg, Deborah A Boggs, Lauren A Wise, Lucile L Adams-Campbell, Julie R Palmer
L Rosenberg, Debbie Boggs, Deb Boggs, D Boggs, L Wise, L Adams-Campbell, J Palmer
PMID 20647407 20647407 DOI 10.1158/1055-9965.EPI-10-0428 10.1158/1055-9965.EPI-10-0428 Rosenberg et al. 2010, Rosenberg 2010